Nothing Special   »   [go: up one dir, main page]

CR20220629A - Moléculas de unión al dominio fc de activación inmunitaria - Google Patents

Moléculas de unión al dominio fc de activación inmunitaria

Info

Publication number
CR20220629A
CR20220629A CR20220629A CR20220629A CR20220629A CR 20220629 A CR20220629 A CR 20220629A CR 20220629 A CR20220629 A CR 20220629A CR 20220629 A CR20220629 A CR 20220629A CR 20220629 A CR20220629 A CR 20220629A
Authority
CR
Costa Rica
Prior art keywords
binding molecules
domain binding
immune activating
methods
molecules
Prior art date
Application number
CR20220629A
Other languages
English (en)
Inventor
Thomas Hofer
Diana Darowski
Laura Lauener
Pablo Umana
Anne Freimoser-Grundschober
Marlena Surówka
Koller Claudia Ferrara
Stephane Leclair
Ekkehard Moessner
Christian Klein
Christina Claus
Maria Amann
Christiane Neumann
Ali Bransi
Tanja Fauti
Gutierrez Cirlos Alejandro Carpy
Sylvia Herter
Deak Laura Codarri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220629A publication Critical patent/CR20220629A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere generalmente a moléculas de unión al dominio Fc de activación inmunitaria para la activación de las células inmunitarias y el redireccionamiento a células diana específicas. Además, la presente invención se refiere a polinucleótidos que codifican tales moléculas, y vectores y células huésped que comprenden tales polinucleótidos. La invención se refiere además a los procedimientos para producir las moléculas de unión a antígeno biespecíficas de la invención, y a los procedimientos para usar estas moléculas de unión a antígeno biespecíficas en el tratamiento de una enfermedad
CR20220629A 2020-06-19 2021-06-17 Moléculas de unión al dominio fc de activación inmunitaria CR20220629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181087 2020-06-19
PCT/EP2021/066337 WO2021255138A1 (en) 2020-06-19 2021-06-17 Immune activating fc domain binding molecules

Publications (1)

Publication Number Publication Date
CR20220629A true CR20220629A (es) 2023-02-17

Family

ID=71111338

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220629A CR20220629A (es) 2020-06-19 2021-06-17 Moléculas de unión al dominio fc de activación inmunitaria

Country Status (17)

Country Link
US (1) US20240043535A1 (es)
EP (1) EP4168445A1 (es)
JP (1) JP2023529981A (es)
KR (1) KR20230025783A (es)
CN (1) CN115916827A (es)
AR (1) AR122657A1 (es)
AU (1) AU2021291405A1 (es)
BR (1) BR112022025250A2 (es)
CA (1) CA3176552A1 (es)
CL (1) CL2022003637A1 (es)
CO (1) CO2022019317A2 (es)
CR (1) CR20220629A (es)
IL (1) IL296225A (es)
MX (1) MX2022015203A (es)
PE (1) PE20230470A1 (es)
TW (1) TW202219065A (es)
WO (1) WO2021255138A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118271445A (zh) 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体
AU2021291011A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and CD19
MX2024009715A (es) * 2022-02-11 2024-08-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Inmunoconjugado y su uso del mismo.
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
AR128876A1 (es) * 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
WO2024052389A1 (en) * 2022-09-08 2024-03-14 F. Hoffmann-La Roche Ag Recombinant t cell receptors
CN118477173A (zh) * 2023-02-13 2024-08-13 信达细胞制药(苏州)有限公司 靶向HER2/p95HER2的P329G抗体及其与嵌合抗原受体细胞的组合和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1196570A2 (en) 1999-07-26 2002-04-17 Genentech, Inc. Human polypeptides and methods for the use thereof
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
MXPA04005266A (es) 2001-12-04 2004-10-11 Merck Patent Gmbh Inmunocitocinas con selectividad modulada.
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN101115773B (zh) 2005-02-07 2015-06-10 罗氏格黎卡特股份公司 结合egfr的抗原结合分子,编码它的载体,及其应用
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
SI1999154T1 (sl) 2006-03-24 2013-01-31 Merck Patent Gmbh Heterodimerne, z genskim inĺ˝eniringom spremenjene proteinske domene
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
EP3505636A1 (en) 2009-04-27 2019-07-03 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX341796B (es) 2009-12-29 2016-09-02 Emergent Product Dev Seattle Proteinas de union heterodimericas y usos de las mismas.
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SI3489255T1 (sl) 2011-02-10 2021-11-30 Roche Glycart Ag Mutantni polipeptidi interlevkina-2
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
EP2961771B1 (en) 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR20180069065A (ko) 2015-10-29 2018-06-22 에프. 호프만-라 로슈 아게 항-변이체 fc-부위 항체 및 사용 방법
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體

Also Published As

Publication number Publication date
KR20230025783A (ko) 2023-02-23
TW202219065A (zh) 2022-05-16
PE20230470A1 (es) 2023-03-14
CL2022003637A1 (es) 2023-06-23
CN115916827A (zh) 2023-04-04
CA3176552A1 (en) 2021-12-23
JP2023529981A (ja) 2023-07-12
MX2022015203A (es) 2023-01-05
US20240043535A1 (en) 2024-02-08
EP4168445A1 (en) 2023-04-26
WO2021255138A1 (en) 2021-12-23
IL296225A (en) 2022-11-01
AU2021291405A1 (en) 2022-09-29
AR122657A1 (es) 2022-09-28
CO2022019317A2 (es) 2023-03-27
BR112022025250A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
MX2022015203A (es) Moleculas de union al dominio fc de activacion inmunitaria.
PH12020551211A1 (en) Antibodies binding to gprc5d
MX2022001156A (es) Anticuerpos que se fijan a gprc5d.
MX2021007307A (es) Anticuerpos que se unen a cd3.
MX2018003631A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
WO2017055388A3 (en) Bispecific t cell activating antigen binding molecules
MX2017006571A (es) Moleculas de union a antigeno biespecificas activadoras de celulas t.
SG10201803384TA (en) Bispecific t cell activating antigen binding molecules
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
MX352101B (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2022003110A (es) Anticuerpos biespecificos contra ceacam5 y cd3.
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
MX2022015204A (es) Anticuerpos que se unen a cd3.
TN2017000488A1 (en) Antibodies against ox40 and uses thereof
MX2022007635A (es) Anticuerpos que se unen a hla-a2/mage-a4.
EP3747899A3 (en) High avidity binding molecules recognizing mage-a1
MX2022016069A (es) Anticuerpos que se unen a cd3 y cd19.
WO2019122052A3 (en) Antibodies binding to hla-a2/wt1
PH12019502274A1 (en) Antibodies binding to steap-1
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MX2023007220A (es) Anticuerpos biespecificos contra el antigeno carcinoembrionario humano (ceacam5) y el cumulo de diferenciacion 47 (cd47).